AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8126691 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 76
Study 2508791 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg)
Number of subjects: 10
Study 2508791 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 2508791 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate
Number of subjects: 10
Study 412099 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (150 mg of trimethoprim and 750 mg of sulfamethoxazole per square meter per day)
Number of subjects: 160
Study 412099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 412099 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 160
Study 30476131 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically elevated C-reactive protein (CRP) concentration
Number of subjects: 30580
Study 30476131 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-associated SNPs (rs1260326 and rs6734238)
Number of subjects: 30580
Study 27836905 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB) with ropivacaine infusion for 2 days and oxycodone
Number of subjects: 74
Study 27836905 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesic (IV PCA) of morphine
Number of subjects: 74
Study 27836905 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 74
Study 26070650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education (intervention group)
Number of subjects: 202
Study 26070650 — intervention group
Group type: COMPARATOR
Intervention: Sham education (control group)
Number of subjects: 202
Study 23771842 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with low-income patients managing diabetes
Number of subjects: 20
Study 23771842 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic attempts at incorporating healthy dietary practices
Number of subjects: 20
Study 23771842 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care provider recommendations
Number of subjects: 20
Study 21672204 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral supplement
Number of subjects: 817
Study 21672204 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trial survey
Number of subjects: 817
Study 21672204 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmasking offer
Number of subjects: 817
Study 19928391 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg of MDMA
Number of subjects: 20
Study 19928391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19928391 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction (positive control)
Number of subjects: 20
Study 16739854 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 15
Study 16739854 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (Control)
Number of subjects: 15
Study 15217028 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based problem-solving therapy
Number of subjects: 54
Study 15217028 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based stress-management training
Number of subjects: 54
Study 15217028 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 54
Study 12539568 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.1 mg.kg‐1.min‐1)
Number of subjects: 30
Study 12539568 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (5 micrograms.kg‐1.min‐1)
Number of subjects: 30
Study 9416719 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled interscalene analgesia (PCIA) with 0.15% bupivacaine, continuous infusion at 5 ml/h plus bolus of 3 or 4 ml with a lock-time of 20 min.
Number of subjects: 40
Study 9416719 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with nicomorphine, continuous infusion at 0.5 mg/h plus bolus of 2 or 3 mg with a lock-time of 20 min.
Number of subjects: 40
Study 8233295 — intervention group
Group type: EXPERIMENTAL
Intervention: CVM (carboplatin/vinblastine/methotrexate)
Number of subjects: 104
Study 8233295 — intervention group
Group type: COMPARATOR
Intervention: ACE (doxorubicin/cyclophosphamide/etoposide)
Number of subjects: 104
Study 8233295 — intervention group
Group type: EXPERIMENTAL
Intervention: CVM
Number of subjects: 104
Study 8233295 — intervention group
Group type: COMPARATOR
Intervention: ACE
Number of subjects: 104
Study 3815837 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Bupivacaine (50 mg)
Number of subjects: 60
Study 3815837 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Bupivacaine (25 mg)
Number of subjects: 60
Study 3815837 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin administration during the block
Number of subjects: 60
Study 3815837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of Bupivacaine
Number of subjects: 60
Study 30556233 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program (3 times per week, 40 min per session for 6 months)
Number of subjects: 133
Study 30556233 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair-bound Senior Elastic Band exercise program
Number of subjects: 133
Study 28821427 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training one time per week (EX1)
Number of subjects: 106
Study 28821427 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training two times per week (EX2)
Number of subjects: 106
Study 28821427 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training three times per week (EX3)
Number of subjects: 106
Study 28821427 — intervention group
Group type: COMPARATOR
Intervention: Non-training control group (CON)
Number of subjects: 106
Study 25575620 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (200 μg)
Number of subjects: 16
Study 25575620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23168399 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Resistance Program (MRP) at 75% of maximum load, 10 weeks, 3 times/week
Number of subjects: 32
Study 23168399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of Muscle Resistance Program (MRP) after 10 weeks
Number of subjects: 32
Study 20980126 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention modification paradigm designed to influence selective engagement with threat meanings
Number of subjects: 0
Study 20980126 — intervention group
Group type: COMPARATOR
Intervention: Attention modification paradigm designed to influence selective disengagement from threat meanings
Number of subjects: 0
Study 18089634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 12 mg/kg/year
Number of subjects: 12
Study 18089634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 6 mg/kg/year
Number of subjects: 12
Study 18089634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (both doses)
Number of subjects: 12
Study 16968913 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine phosphate (30 mg base daily for 14 days for PART; 30 mg daily for primary prophylaxis)
Number of subjects: 0
Study 15248876 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 61
Study 15248876 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 61
Study 15248876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMZ and Brånemark implants
Number of subjects: 61
Study 15248876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic revisions
Number of subjects: 61
Study 11335737 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air resuscitation (RAR)
Number of subjects: 0
Study 11335737 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen resuscitation (OxR)
Number of subjects: 0
Study 9352971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (0.625 mg)
Number of subjects: 20
Study 9352971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8302922 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at 0.1 microgram.kg‐1.min‐1
Number of subjects: 30
Study 8302922 — intervention group
Group type: COMPARATOR
Intervention: Trimethaphan (TMP) at 10 micrograms.kg‐1.min‐1
Number of subjects: 30
Study 3539826 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral timolol
Number of subjects: 132
Study 3539826 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 132
Study 28730396 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS for Life intervention administered by trained teachers
Number of subjects: 695
Study 28730396 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS for Life intervention for children with elevated depressive symptoms at baseline
Number of subjects: 695
Study 28730396 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS for Life intervention with teachers attending more supervision sessions
Number of subjects: 695
Study 28730396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 695
Study 26360125 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release tacrolimus
Number of subjects: 91
Study 26360125 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily tacrolimus
Number of subjects: 91
Study 24678064 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cocaine
Number of subjects: 37
Study 24678064 — intervention group
Group type: COMPARATOR
Intervention: Topical adrenaline
Number of subjects: 37
Study 21308791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and ezetimibe on top of oral anticoagulation therapy
Number of subjects: 34
Study 21308791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20519663 — intervention group
Group type: COMPARATOR
Intervention: Control arm with standard advice (IDPP-1)
Number of subjects: 845
Study 20519663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 845
Study 20519663 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n = 125, IDPP-1)
Number of subjects: 845
Study 20519663 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM + Metformin (n = 121, IDPP-1)
Number of subjects: 845
Study 20519663 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM + Pioglitazone (n = 298, IDPP-2)
Number of subjects: 845
Study 18509244 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 administration for 6 months
Number of subjects: 36
Study 11169027 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan hemodialysis (HD)
Number of subjects: 27
Study 11169027 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis (PD)
Number of subjects: 27
Study 11169027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux polysulfon (F6 HPS)
Number of subjects: 27
Study 11169027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfon (F60S)
Number of subjects: 27
Study 11169027 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 9987422 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding campaign (panel presentation and video)
Number of subjects: 412
Study 9987422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to the campaign)
Number of subjects: 412
Study 7841431 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT
Number of subjects: 122
Study 7841431 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE
Number of subjects: 122
Study 7841431 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE (Male African group)
Number of subjects: 122
Study 3168077 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon treatment (5 IU three times weekly by subcutaneous injection for 16 weeks)
Number of subjects: 20
Study 3168077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 3168077 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon treatment
Number of subjects: 20
Study 29792234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 134
Study 29792234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 134
Study 29871264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray combined with montelukast (MOM+M)
Number of subjects: 57
Study 29871264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray combined with loratadine (MOM+L)
Number of subjects: 57
Study 29871264 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate aqueous nasal spray (MOM)
Number of subjects: 57
Study 25052218 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injector
Number of subjects: 53
Study 25052218 — intervention group
Group type: COMPARATOR
Intervention: Needle infiltration
Number of subjects: 53
Study 23998952 — intervention group
Group type: EXPERIMENTAL
Intervention: ITAREPS
Number of subjects: 45
Study 21466700 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (simple end-to-end repair of the tendon with no augmentation)
Number of subjects: 52
Study 21466700 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 52
Study 21466700 — intervention group
Group type: COMPARATOR
Intervention: Parallel patient preference group (non-operative management)
Number of subjects: 52
Study 18050368 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate disodium (200 mg per day for 2 weeks) with 3.0 g of calcium lactate and 0.75 microg of alphacalcidol daily
Number of subjects: 102
Study 18050368 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only calcium lactate and alphacalcidol
Number of subjects: 102
Study 18050368 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate disodium
Number of subjects: 102
Study 16412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 850
Study 16412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 850
Study 16412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 850
Study 16412157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study 12519633 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10852452 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (Evista, 60 mg/day)
Number of subjects: 100
Study 10852452 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE; Premarin, 0.625 mg/day)
Number of subjects: 100
Study 9337603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR) followed by exposure (EXP)
Number of subjects: 60
Study 9337603 — intervention group
Group type: COMPARATOR
Intervention: Control intervention followed by exposure (EXP)
Number of subjects: 60
Study 8096389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate patches releasing 15 mg/24 h
Number of subjects: 14
Study 8096389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30259284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 153
Study 29409556 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Default (OD)
Number of subjects: 129
Study 29409556 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Array (FA)
Number of subjects: 129
Study 29409556 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal Default (SD)
Number of subjects: 129
Study 27386644 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaozhu Yinchen Recipe (ZZYCR), one dose per day for 24 weeks
Number of subjects: 120
Study 27386644 — intervention group
Group type: COMPARATOR
Intervention: Silibin Meglumine Tablets, 20 mg thrice per day for 24 weeks
Number of subjects: 120
Study 25238831 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (workshops on nutrition and physical activity)
Number of subjects: 126
Study 23063038 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system
Number of subjects: 10
Study 23063038 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (OL) system
Number of subjects: 10
Study 20013441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix A of food additives
Number of subjects: 1035
Study 20013441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix B of food additives
Number of subjects: 1035
Study 20013441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (preservative)
Number of subjects: 1035
Study 20013441 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intake of food additives
Number of subjects: 1035
Study 18374003 — intervention group
Group type: EXPERIMENTAL
Intervention: FES cycling at 15 rpm
Number of subjects: 9
Study 18374003 — intervention group
Group type: EXPERIMENTAL
Intervention: FES cycling at 30 rpm
Number of subjects: 9
Study 18374003 — intervention group
Group type: EXPERIMENTAL
Intervention: FES cycling at 50 rpm
Number of subjects: 9
Study 18374003 — intervention group
Group type: COMPARATOR
Intervention: FES cycling at 15, 30, and 50 rpm
Number of subjects: 9
Study 17409936 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 105Val allele
Number of subjects: 108
Study 17409936 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1*B haplotype
Number of subjects: 108
Study 17409936 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 polymorphisms
Number of subjects: 108
Study 17409936 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 105Val allele and GSTP1*B allele
Number of subjects: 108
Study 12821739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cooling therapy for 1 hour
Number of subjects: 84
Study 12821739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cooling therapy for 1 hour
Number of subjects: 84
Study 12821739 — intervention group
Group type: COMPARATOR
Intervention: Daily cooling garment use for 1 hour each day for a month
Number of subjects: 84
Study 12821739 — intervention group
Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 84
Study 10834668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at a target plasma concentration of 100 ng/mL
Number of subjects: 8
Study 10834668 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at a target plasma concentration of 200 ng/mL
Number of subjects: 8
Study 10834668 — intervention group
Group type: COMPARATOR
Intervention: None (control)
Number of subjects: 8
Study 9002092 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day Acuvue disposable soft contact lenses (BC 9.0 mm, diameter 14.2 mm)
Number of subjects: 25
Study 9002092 — intervention group
Group type: COMPARATOR
Intervention: 14-day Acuvue disposable soft contact lenses (BC 8.8 mm, diameter 14.0 mm)
Number of subjects: 25
Study 1455324 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 110
Study 1455324 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 110
Study 1455324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 3975735 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage via Penrose dam
Number of subjects: 161
Study 3975735 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 161
Study 31437195 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss ≥500ml
Number of subjects: 2335
Study 31437195 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss ≥1000ml
Number of subjects: 2335
Study 31437195 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss 500-999 ml
Number of subjects: 2335
Study 29017803 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated mobile phone messaging
Number of subjects: 34
Study 29017803 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical TJA patients)
Number of subjects: 34
Study 27094106 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 998
Study 24418950 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 613
Study 24418950 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 613
Study 23153014 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote care (telehealth and telecare)
Number of subjects: 3
Study 19665936 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 80 pps
Number of subjects: 32
Study 19665936 — intervention group
Group type: COMPARATOR
Intervention: TENS at 3 pps
Number of subjects: 32
Study 19665936 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TENS at 80 pps vs 3 pps
Number of subjects: 32
Study 18265584 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 77
Study 18265584 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan's method
Number of subjects: 77
Study 15934285 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy and IFN‐gamma treatment (1000000 IU im qod)
Number of subjects: 60
Study 15934285 — intervention group
Group type: COMPARATOR
Intervention: Specific immunotherapy (control group)
Number of subjects: 60
Study 12468782 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg/d for 2 to 8 weeks
Number of subjects: 100
Study 12468782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9785786 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Number of subjects: 40
Study 9785786 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with propofol (1 mg.kg‐1 bolus followed by 4 mg.kg‐1.h‐1 continuous infusion)
Number of subjects: 40
Study 7894881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 62
Study 7894881 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant alone (placebo)
Number of subjects: 62
Study 2692686 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 0
Study 2692686 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime and Metronidazole
Number of subjects: 0